

Nomura Research Institute (4307.T): Earnings in line, guidance above expectations; stable growth continues on strong domestic business

NRI reported 4Q (January-March) and full-year FY3/25 earnings after the April 24 close. FY3/25 operating profits of ¥134.9 bn (+12% yoy) and FY3/26 operating profit guidance of ¥150 bn (+11% yoy) were both in line with Bloomberg consensus forecasts (¥135.2 bn and ¥149 bn, respectively). However, the guidance for operating profits above the FY3/26 target of ¥145 bn under the medium-term plan came as a surprise given concerns about a potential deterioration in business sentiment due to reciprocal tariffs. According to NRI, the scale of development work on projects already acquired in the domestic industrial IT business is expanding, mainly in 2H, and the overseas business is also expected to recover gradually. Although the overseas business environment remains challenging, domestic business is strong overall (including the pipeline), and NRI said there are currently no signs of investment curbs due to worsening business sentiment. We think profit guidance is somewhat aggressive and remain cautious given order trends (up 3% yoy in 4Q3/25) and uncertainty about the overseas business outlook, but NRI stated at the results briefing that strength in the domestic business can offset uncertainty overseas. There was no new information on the application of generative AI to systems development, and we believe the impact on FY3/26 earnings will be limited. While strong profit growth looks set to continue, this is already reflected in valuations, with P/E of 29.4X (based on FY3/26 guidance) well above the sector average. We maintain our Neutral rating.

- 4Q3/25 earnings: 4Q operating profits continued to register double-digit (%) growth, rising 12%/+¥3.4 bn yoy to ¥32.6 bn. By segment, growth was driven by consulting (+28%/+¥1.2 bn yoy), where demand is strong, IT platform services (+24%/+¥1.5 bn yoy), and financial IT solutions (+16%/+¥2 bn yoy), where system integration projects for banks are expanding. On the other hand, industrial IT profits declined 26%/-¥1.46 bn yoy, with domestic profits down 2%/-¥0.1 bn yoy and overseas profits down ¥1.36 bn yoy. This reflected investment curbs at a convenience store customer in Japan, and weaker demand/restructuring costs (in the mid-single-digit billions of yen) in Australia. 4Q orders rose 3% yoy, with domestic orders (also up 3% overall) roughly flat to slightly higher in both financial IT solutions and industrial IT.
- **FY3/26 guidance:** FY3/26 operating profit guidance of ¥150 bn (+11% yoy) is higher than the medium-term plan target (¥145 bn) despite concerns about a

Chikai Tanaka, CFA +81(3)4587-9840 | chikai.tanaka@gs.com Goldman Sachs Japan Co., Ltd.

Moriya Koketsu +81(3)4587-9875 | moriya.koketsu@gs.com Goldman Sachs Japan Co., Ltd.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

potential deterioration in business sentiment due to reciprocal tariffs. This is mainly due to stronger-than-expected inquiries in domestic financial IT solutions and domestic industrial IT. According to NRI, although orders were only up slightly in 4Q3/25, the industrial IT pipeline is expanding, mainly among domestic-demand customers (reciprocal tariffs have a relatively small impact on domestic demand), and there is potential for large project wins with multiple customers in financial IT solutions. By region, guidance calls for 10%/+¥13.6 bn yoy operating profit growth in Japan and 68%/+¥1.45 bn yoy growth overseas. We see no issues with the growth assumptions, centered on the domestic business. We think NRI as a more defensive play than peers (high recurring revenue weighting) and expect stable growth in companywide earnings. However, we will closely monitor downside risks such as investment trends at a major convenience store customer in Japan (potential for investment cuts) and the demand environment in Australia and North America (potential for further deterioration in business sentiment).

Exhibit 1: 403/25 OP strong, led by consulting, IT platform services, and financial IT solutions; FY3/26 OP guidance calls for continued double-digit (%) yoy growth

NRI: Earnings by business

Section 197, 169 29,085 190,086 197,086 184,077 277,085 190,086 277,085 197,086 197,	(in million yen)	1		CoE	24/3				25/3			
		24/3	25/3	26/3	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2		755.044	702.024		422.020	440.005	404 000	400 400	444.000	400.000	444444	445 004
Decide 97,446 28,962 32,973 26,862 109,869 397,469 24,772 27,965			,									3.2%
Speciming												428,582
Company												7.9%
Gross profits 261,006 275,35 303,000 63,70 63,03 64,07 63,03 64,07 63,08 67,06 71,06 70,00 70,08 67,00 70,08 67,00 70,08 67,00 70,08 70,00 70,				,					,			
Section												69,709
142.953 144.07 153.00 3.25 145.07 153.00 3.25 3.2	у-у											5.6%
y y so f asiles 19.5% 12.9% 1	% of sales											35.5%
Second productions arithmus accompromises 1,757 3,683 0												
Comparison profitions and emproprisons 1,787 3,863 0 490 438 1,985 156 1,453 1,008 808 41 134,907 14,000 27,007 1,158 1,353 1,353 1,274 1,275												19.1%
Variety 1,7% 1,20% 1,12% 3,37% 17,1% 13,2% 4,3% 20,8% 3,0% 3,0% 1,0%												416
Subuniess aggments 16.3% 17.0% 18.5% 17.2% 15.9% 17.2% 15.9% 17.4% 17.5% 19.2% 10.0%												32,554
Consulting												
Section		10.070	11.070	10.070	10.070	11.270	11.270	10.070	111170	11.070	10.270	10.070
14.6% 20.2% 20.												
Display												11,523
Lettorial Sales												
12,7% 16,1% 12,7% 16,1% 12,7% 16,0% 20,5% 8,1% 10,2% 10,1% 10,5% 19,0% 14,0% 15,0	-											26.7%
Variable Properties Prop				,								16,699
Department 13,929 18,388 2,147 3,628 3,818 4,338 2,775 4,289 3,098 3,075 27,898 3,0898 3,0												14.4%
13.0% 32.1% 15.5% 18.8% 11.6% 8.5% 20.3% 30.9% 39.7% 27.8% 27.8% 28.8% 30.9%				6.4%								8.5% 5,542
Section Sec								8.5%				27.8%
Order 366,379 386,238 47,027 48,039 44,415 27,498 48,570 57,081 51,146 224,747 57,097 50,000 53,000	% of sales	25.9%	28.1%		19.1%		27.1%		20.4%	29.5%	30.6%	30.3%
Product		366 070	386 220		47 027	48 030	11 11 F	227 409	48 570	57.054	51 146	229 474
Order Backlog 229,888 249,908 249,908 249,008 15,75 15,85 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,88 13,22 13,68 40,98 47,58 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 40,98 41,98 40,98 41,98 40,98 41,90 14,98 40,98 41,90 15,28							,		,	. ,		0.9%
External Sales												249,908
by 6.5% 4.8% 4.7% 7.1% 5.0% 9.1% 7.1% 3.0% 4.0% 4.7% 4.7% 4.7% 4.7% 5.0% 9.1% 7.1% 3.0% 4.0% 4.7% 4.7% 4.0% 4.5% 4.0% 4.7% 4.7% 4.7% 4.7% 4.7% 5.0% 9.1% 5.053 30.30 30.70 30.503 30.30 3.2,10 30.00 20.00<												8.7%
Securities												
Insurance												47.6%
Banking	Securities											37,584
Cher Financials												21,546
Second Sales (New definition) Second Sales (New definition) Second Sales												
March Mar		00,010		380,000	,00 .	.0,0.0	,	,020	.0,200	.0,.00	.0,022	.0,.02
Departing profits	у-у		-									
Y-y 9.9% 12.5% 4.2% 22.4% 7.8% 6.1% 26.6% 3.7% 6.9% 15.7% 6.7% 15.7				46.9%	40.470	44.000	45.050	40.005	45 404	44.700	40 407	44.050
Mindustrial IT Solutions												
Part												15.7%
byy 2.2% -1.8% 3.1% 8.5% -12.0% 4.1% -3.4% -5.4% 5.4% 131,73 Order Backlog 128,275 113,173 112,349 92,238 58,657 128,275 111,213 86,509 58,797 131,173 External Sales 275,923 266,787 69,426 70,631 69,295 66,571 70,427 66,992 64,496 64,395 -2.6% % of sales 37,5% 34,9% 39,3% 38,1% 36,9% 35,7% 37,4% 35,5% 42,2% Manufacturing, service and other 204,395 24,830 29,000 51,880 51,847 19,47 49,518 53,913 51,219 49,520 50,177 External Sales (New definition) 22,483 35,0% 35,8% 25,890 6,431 5,487 5,597 6,671 7,437 6,001 4,13 y-y 4,1% 3,2% 3,8% 8,8% 8,3% 8,9% 7,8% 6,571 7,437 6,001												
Order Backlog 128,275 131,173 112,349 92,238 58,657 128,275 111,318 65,09 58,797 131,173 21,3% 1-0,7% -0.8% -12,1% -1.3% -1.0% -6.2% 0.2% 22,32 23,7% -2.0% -0.2% -6.2% 0.2% 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.23 66,571 70,427 66,922 64,956 6.97 2.23 66,571 70,427 66,925 6,957 -5.0% -6.9% 2.20 0.33 3.3% 3.6% 3.74% 3.55% 3.37 3.4 3.3% 3.3% 3.8% 3.5,80							,		,			
Part												
External Sales	· ·											2.3%
% of sales 37.5% 34.9% 39.3% 38.1% 36.9% 35.7% 37.4% 35.5% 33.7% 33.0% 33.0% 38.1% 36.9% 35.7% 37.4% 35.5% 33.7% 33.0% 33.0% 33.0% 38.1% 36.9% 35.7% 37.4% 35.5% 33.7% 33.0% 33.0% 38.8% 17.08 18.08 18.00 18.08 18.00 18.08			, .							,		64,872
Distribution 71,528 61,957 204,830 2												
Manufacturing, service and other 204,395 204,830 290,000 267,487 290,000 290,000 267,487 290,000												33.0% 14,695
Section Sales New definition Section	Manufacturing, service and other											50,178
% of sales 35.0% Operating profits 23,405 24,247 24,247 5,890 6,431 5,487 5,597 6,671 7,437 6,001 4,131 7,27 8,001 4,131 7,27 8,001 8,30 8,80 8,80 8,80 8,80 8,80 8,80 8,80	External Sales (New definition)		267,487									
Operating profits 23,405 24,247 5,890 6,431 5,487 5,597 6,671 7,437 6,001 4,133 y-y 4.1% 3.6% 11.7% 4.4% 10.0% -6,9% 13.3% 15.6% 9.4% -26.1% % 0f sales 8.3% 8.8% 8.3% 8.9% 7.8% 8.2% 9.3% 10.6% 9.4% -26.1% 9.4% -26.1% 9.4% -26.1% 9.4% -26.1% 9.4% -26.1% 9.8% 10.078 8.2% 9.3% 10.8% 9.0% 6.29 WIT Platform Services Order 61,367 73,293 13,103 9.845 10,078 28,341 13,287 11,490 126,32 35,344 y.7 14,96 12,947 21,790 25.7% 8.2% 22.9% 5.5% 16,7% 25.3% 24.7% 7.2% 7.2% 22.9% 5.5% 16,7% 25.3% 24.7% 7.2% 7.9% 8.2% 22.9% 25.9% 20.2% 27.7% <t< td=""><td></td><td></td><td>35.0%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>			35.0%									
y-y % of sales -4.1% 8.3% 3.6% 8.8% -11.7% 8.3% 4.4% 8.9% 10.0% 7.8% -6.9% 8.2% 13.3% 9.3% 15.6% 10.8% 9.4% 9.0% -26.1% 6.29 WIT Platform Services Order 61,367 19.6% 73,293 19.6% 13,103 17.9% 9.845 25.7% 10,078 8.2% 28,341 22.9% 13,827 5.5% 11,490 16.7% 12,632 25.3% 23,342 24.79 Order Backlog y-y 26,427 27.7% 31,974 27.7% 21,002 21,002 17,808 21,302 13,808 21,302 26,427 25,337 21,491 25,337 21,491 25,337 21,491 25,337 21,491 25,337 21,491 25,337 11,490 25,302 27,706 21,002 21,002 27,706 21,002 21,002 27,706 21,002 20,202 27,706 27,707 21,002 21,002 27,706 21,002 21,002 27,707 21,002 21,002 21,002 21,002 21,002 27,707 21,002 21,002 21,002 21,002 21		23.405		33.8%	5.890	6.431	5.487	5.597	6.671	7.437	6.001	4,138
WIT Platform Services												-26.1%
Order 61,367 73,293 13,103 9,845 10,078 28,341 13,827 11,490 12,632 35,344 y-y 19.6% 19.4% 17.9% 25.7% 8.2% 22.9% 5.5% 16.7% 25.3% 24.79 Order Backlog 26,427 31,974 21,302 17,808 13,081 26,427 25,337 21,491 17,219 31,974 y-y 27.7% 21.0% 19.9% 25.9% 20.2% 27.7% 18.9% 20.7% 31.6% 21.97 External Sales 55,628 67,746 12,489 13,339 14,805 14,995 14,918 15,335 16,904 20,589 y-y 15.5% 21.8% 14,9% 16.4% 17.7% 13.2% 19.4% 15.0% 14.2% 37.3% % of sales 7.6% 8.9% 7.1% 7.2% 7.9% 8.0% 7.9% 8.1% 8.8% 10.5% External Sales (New definition) 8.8% 8.8%		8.3%	8.8%		8.3%	8.9%	7.8%	8.2%	9.3%	10.8%	9.0%	6.2%
y-y Order Backlog 19.6% 26,427 19.4% 31,974 17.9% 21,302 25.7% 21,302 8.2% 21,302 22.9% 25.9% 5.5% 25,337 16.7% 25,337 24.79 21,491 24.79 31,974 24.79 21,002 27.7% 21.0% 21,002 25.9% 20.2% 20.2% 27.7% 27.7% 18.9% 20.2% 27.7% 21.0% 21.0% 21.0% 21.0% 25.9% 20.2% 20.2% 27.7% 27.7% 18.9% 20.7% 21.0% 20.7% 21.0% 20.7% 21.0% 20.7% 21.0% 20.0% 20.2% 20.2% 14.995 20.2% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.2% 14.995 20.2% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.995 20.7% 14.2% 15.0% 20.0% 12.9% 20.0% 15.0% 20.0% 12.9% 20.0% 10.0% 20.0% <		61 367	73 293		13 103	9 845	10 078	28 341	13 827	11 490	12 632	35 344
Order Backlog 26,427 31,974 21,302 17,808 13,081 26,427 21,491 17,219 31,974 y-y 27.7% 21.0% 19.9% 25,98% 20.2% 27.7% 18.9% 21.0% 31,697 21.0% 21.0% 19.9% 25.9% 20.2% 27.7% 18.9% 20.0% 31,697 21.0% 21.0% 21.0% 14.995 14,805 14,995 19,491 15,095 29,585 29,779 8.0% 7.9% 8.0% 7.9% 8.0% 7.9% 8.0% 7.9% 8.10% 8.0% 10.5% 9.0% 8.0% 7.9% 8.0% 7.9% 8.0% 7.9% 8.10% 8.10% 8.8% 7.76						,	,					24.7%
External Sales 55,628 67,746 12,489 13,339 14,805 14,995 14,918 15,335 16,904 20,588		26,427	31,974		21,302	17,808	13,081	26,427	25,337	21,491	17,219	31,974
y-y 15.5% 21.8% 14.9% 16.4% 17.7% 13.2% 19.4% 15.0% 14.2% 37.3% % of sales 67,041 68,000 7.1% 7.2% 7.9% 8.0% 7.9% 8.1% 8.8% 10.5% y-y 1.4% 8.8% 8.4% 8.4% 6,750 7,543 7,634 6,240 7,756 6,059 8,887 7,766 Operating profits 28,167 30,470 6,750 7,543 7,634 6,240 7,756 6,059 8,887 7,766 y-y 22.2% 8.2% 20.6% 29.3% 28.2% 10.2% 14.9% -19.7% 16.4% 24.5% y-y 22.2% 8.2% 15.1% 15.4% 16.5% 16.0% 12.9% 14.9% -19.7% 16.4% 24.5% y-y 22.2% 8.2% 8.2% 15.4% 16.5% 16.0% 12.9% 14.9% -19.7% 16.4% 24.5% 15.4% 16.5% 1												21.0%
% of sales 7.6% 8.9% 7.0% 7.2% 7.9% 8.0% 7.9% 8.1% 8.8% 10.5% External Sales (New definition) 67,041 68,000 7.1% 7.2% 7.9% 8.0% 7.9% 8.1% 8.8% 10.5% Ly-y 60 sales 8.8% 8.4% 6.750 7.543 7.634 6.240 7.756 6.059 8.887 7.766 y-y 22.2% 8.2% 20.6% 29.3% 28.2% 10.2% 14.9% -19.7% 16.4% 24.5% % of sales 15.2% 15.1% 15.4% 16.5% 16.0% 12.9% 16.3% 12.4% 17.7% 14.2% Vothers and Elimination 3,370 3,375 804 592 685 1,289 773 480 802 1,300 0thers (Order Backlog) 995 1,004 870 680 578 995 895 535 525 5,00 0thers (Sales) 1,300 780 873 873												20,589 37.3%
External Sales (New definition) 67,041 68,000 y.y 68,000 1.4% 8.8% 8.8% 8.4% 8.8% 8.4% 8.8% 8.4% 8.8% 8.4% 8.8% 9.5% 9.5% 9.5% 9.5% 9.5% 9.5% 9.5% 9.5												37.3% 10.5%
% of sales 8.8% Operating profits 6,750 Operating profits 7,543 Operating profits 7,634 Operating profits 6,240 Operating profits 7,756 Operating profits 8,887 Operating profits 7,766 Operating profits 8,887 Operating profits 7,766 Operating profits 8,887 Operating profits 7,766 Operating profits 8,2% Operating profits 20,6% Operating profits 29,3% Operating profits 8,2% Operating profits 10,2% Operating profits 14,9% Operating profits 16,5% Operating profits 16,5% Operating profits 16,5% Operating profits 16,5% Operating profits 16,2% Operating profits 16,2% Operating profits 16,5% Operating profits												
Operating profits 28,167 30,470 6,750 7,543 7,634 6,240 7,756 6,059 8,887 7,766 y-y 22.2% 8.2% 20.6% 29.3% 28.2% 10.2% 14.9% -19.7% 16.4% 24.5% % of sales 15.2% 15.1% 15.4% 16.5% 16.0% 12.9% 16.3% 12.4% 17.7% 14.2% VOthers and Elimination 70thers (Order) 3,370 3,355 804 592 685 1,289 773 480 802 1,300 Others (Order Backlog) 995 1,004 870 680 578 995 895 535 525 1,000 Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 822			-									
y-y 22.2% 8.2% 20.6% 29.3% 28.2% 10.2% 14.9% -19.7% 16.4% 24.5% % of sales 15.2% 15.1% 15.4% 16.5% 16.0% 12.9% 16.3% 12.4% 17.7% 14.2% Volters (Order) Others (Order Backlog) 995 1,004 870 680 578 995 895 535 525 1,000 Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 822		20 167		8.4%	6 750	7 542	7 624	6 240	7 756	6.050	8 007	7 769
% of sales 15.2% 15.1% 15.4% 16.5% 16.0% 12.9% 16.3% 12.4% 17.7% 14.2% VOthers and Elimination Others (Order) 3,370 3,355 804 592 685 1,289 773 480 802 1,300 Others (Order Backlog) 995 1,004 870 680 578 995 895 525 1,000 Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 82'												7,7 68 24.5%
VOthers and Elimination 3,370 3,355 804 592 685 1,289 773 480 802 1,301 Others (Order) 995 1,004 870 680 578 995 895 535 525 1,004 Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 82	% of sales											14.2%
Others (Order Backlog) 995 1,004 870 680 578 995 895 535 525 1,004 Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 82		2.27-	0.055				225	4 225		105	225	
Others (Sales) 3,172 3,346 4,000 730 782 787 873 873 839 813 82												1,300 1,004
				4,000								821
												0

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

Investment Thesis, Price Target Risks and Methodology - Nomura Research Institute

Investment Thesis - Nomura Research Institute

Nomura Research Institute (Neutral) is a major system integrator with strengths in the development and operation of cloud services for financial services and consulting. In recent years, the company has expanded its market share in these fields on the back of know-how nurtured through systems development for industry. We expect NRI to continue posting record-high profits, leveraging its strengths to propose system-based strategies and provide development and operation services in an era of increasing utilization of IT systems to facilitate management strategies. However, we believe profit growth is likely to remain in line with the sector average for now given headwinds, including struggles in the overseas business and curbs on investment at major industrial customers. Based on these factors, the shares do not look undervalued, in our view.

Price Target Risks and Methodology - Nomura Research Institute

Our 12-month target price of ¥5,300 is based on a target P/E of 30X (derived from the historical 3-year average P/E range and premium to the sector average of 22.0X), and our FY3/26E EPS estimate of ¥178. Key risks include (1) investment at major customers, (2) overseas demand, and (3) unprofitable projects.

4307.T	12m Price Target: ¥5,300		Price: ¥5,347	47 Down		nside: 0.9%	
Neutral		GS Forecast					
			3/24	3/25E	3/26E	3/27E	
Market ca	p: ¥3.1tr / \$21.6bn	Revenue (¥ bn)	736.6	763.4	802.4	841.4	
Enterprise valu	e: ¥3.2tr / \$22.5bn	Op. profit (¥ bn)	120.4	135.0	149.0	163.0	
3m ADTV:	¥8.6bn / \$57.3mn	Op. profit CoE (¥ bn)	-	134.0	_	-	
	Japan	EPS (¥)	136.9	159.3	178.0	197.1	
Japan IT	Services & Telcos	P/E (X)	28.9	33.6	30.0	27.1	
	M&A Rank: 3	P/B (X)	5.7	7.1	6.6	6.0	
Leases incl.	in net debt & EV?: Yes	Dividend yield (%)	1.3	1.2	1.3	1.5	
	res	N debt/EBITDA (ex lease,X)	0.8	0.7	0.5	0.3	
		CROCI (%)	40.5	40.4	40.5	42.9	
			9/24	12/24	3/25E		
		EPS (¥)	40.9	45.7	34.2	-	

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 24 Apr 2025 close.

Disclosure Appendix

Reg AC

We, Chikai Tanaka, CFA and Moriya Koketsu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Nomura Research Institute is/are relative to the other companies in its/their coverage universe: BIPROGY, Fujitsu, KDDI, NEC, NS Solutions, NTT Data, Nippon Telegraph & Telephone, Nomura Research Institute, OBIC, OBIC Business Consultants, Otsuka, SCSK, Softbank Corp., TIS, Trend Micro Inc., freee K.K.

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

There are no company-specific disclosures for: Nomura Research Institute (¥5,347)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	F	Rating Distribution			Investment Banking Relationships				
	Buy	Hold	Sell		Buy	Hold	Sell		
Global	49%	34%	17%		63%	57%	42%		

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

Distribution of ratings: See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at https://www.gs.com/research/hedge.html.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: https://publishing.gs.com/disclosures/hedge.html - /general/equity. Japan: See below. Korea: This research, and any access to it, is intended only for 'professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at:

Goldman Sachs

https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution and the Autorité des marches financiers ("AMF") disseminates research in France; GSI - Succursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research

in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Succursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and <a href="https://www.theocc.com/about/publications/character-risks.jsp and <a href="https://www.theo

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data requity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.